Synlogic, Inc. - Common Stock (SYBX)
Frequently Asked Questions About Synlogic, Inc. - Common Stock (SYBX)
Does Synlogic have any partnerships?
Yes, Synlogic has formed various partnerships and collaborations with academic institutions and pharmaceutical companies to enhance its research capabilities and further its development efforts. Such partnerships can provide financial support, technical expertise, and access to additional resources.
How can investors keep track of Synlogic's financial performance?
Investors can keep track of Synlogic's financial performance by reviewing its quarterly and annual reports filed with the U.S. Securities and Exchange Commission (SEC), which provide insights into the company’s revenue, expenses, clinical trial progress, and overall financial health, along with press releases and investor presentations.
How does Synlogic ensure product safety?
Synlogic adheres to rigorous safety standards throughout its research and development processes. The company conducts thorough preclinical studies and follows stringent regulatory guidelines during clinical trials to evaluate the safety and efficacy of its products before they can be approved for public use.
What diseases does Synlogic aim to address?
Synlogic focuses primarily on rare metabolic diseases and certain gastrointestinal disorders, with its pipeline including products targeting conditions like phenylketonuria (PKU), urea cycle disorders, and various inflammatory diseases, aiming to meet significant unmet medical needs.
What does it mean for Synlogic to be a clinical-stage company?
Being a clinical-stage company means that Synlogic has moved beyond preclinical research and is currently conducting clinical trials to evaluate the safety and efficacy of its drug candidates in humans. This stage is crucial for drug development, as it involves regulatory review and approval before market launch.
What does Synlogic, Inc. do?
Synlogic, Inc. is a clinical-stage biotechnology company that focuses on developing transformative medicines using synthetic biology. The company utilizes its proprietary Synthetic Biotic™ platform to create engineered living medicines that address a range of diseases, particularly metabolic and rare diseases, aiming to provide treatment options through a novel approach to biologics.
What has been a major milestone for Synlogic?
A major milestone for Synlogic was the initiation of its first clinical trial for SYNB001001, which marked a significant step in validating its Synthetic Biotic platform. This trial represents the company's progress in advancing a novel approach to treating rare diseases and showcases the potential of engineered living medicines.
What is SYNB001001?
SYNB001001 is one of Synlogic's key product candidates, designed as an oral therapeutic for treating phenylketonuria (PKU), a rare genetic disorder that can lead to severe cognitive impairment if untreated. By using engineered probiotics, SYNB001001 aims to break down phenylalanine in the intestine, reducing blood levels of this harmful amino acid.
What is the current status of Synlogic's clinical trials?
As of now, Synlogic has several clinical trials underway, including Phase 1 and Phase 2 studies for its lead product candidates. The company continuously updates its clinical trial progress and results, which are critical in advancing its pipeline and attracting potential partnerships.
What is the future outlook for Synlogic, Inc.?
The future outlook for Synlogic, Inc. is promising as it advances its portfolio of Synthetic Biotic product candidates through clinical trials and seeks to expand its therapeutic applications. The ongoing developments in synthetic biology and increasing interest in engineered therapeutics position Synlogic as a potential leader in this innovative space.
What is the importance of synthetic biology in Synlogic's approach?
Synthetic biology is central to Synlogic's approach, allowing the company to design and implement customized biological solutions for medical challenges. This innovative field enables the engineering of live microbes that can be tailored to produce therapeutic effects in patients, illustrating a new paradigm in medicine.
What is the market potential for Synlogic's products?
Synlogic's products have significant market potential, particularly in the realm of rare and complex diseases that currently lack effective treatments. As new treatment modalities emerge, patients and healthcare providers are increasingly seeking innovative therapies, which Synlogic's engineered living medicines aim to fulfill.
What is the role of the Board of Directors at Synlogic?
The Board of Directors plays a critical role in overseeing the strategic direction of Synlogic, ensuring that the company's operations align with its mission and goals. The board includes experienced industry leaders who bring diverse expertise in fields such as biotechnology, finance, and regulatory affairs.
What is the significance of the Nasdaq listing?
Synlogic, Inc. is listed on the Nasdaq stock exchange under the ticker symbol SYBX. This listing not only provides the company with access to capital markets to fund its research and development efforts, but it also enhances visibility and credibility in the biotech industry.
What is the Synthetic Biotic platform?
The Synthetic Biotic platform is Synlogic's proprietary technology that combines synthetic biology, genetics, and microbiology to engineer natural microorganisms into therapeutic agents. These engineered microbes are designed to diagnose and treat diseases by producing therapeutic compounds or modulating biological pathways in the body.
When was Synlogic, Inc. founded?
Synlogic, Inc. was founded in 2014, emerging from research at MIT that aims to leverage synthetic biology to create engineered microbes capable of treating disease. Since its inception, the company has been dedicated to advancing its Synthetic Biotic platform and pipeline.
Where is Synlogic, Inc. headquartered?
Synlogic, Inc. is headquartered in Cambridge, Massachusetts, a hub for biotechnology and life sciences innovation. This location provides the company access to a vibrant community of researchers, industry professionals, and collaboration opportunities.
Who are the main competitors of Synlogic?
Synlogic competes with other biotech companies focused on synthetic biology and engineered therapeutics, such as Zymeworks, Synlogic's key differentiation lies in its specialized focus on developing engineered probiotics for direct administration and localized therapeutic effects.
Who is the CEO of Synlogic, Inc.?
The CEO of Synlogic, Inc. is Dr. T. Ryan McClellan. He has extensive experience in biotechnology and has been key in guiding the company since its formation, focusing on strategic development and investment to further Synlogic's innovative research in synthetic biology.
What is the current price of Synlogic, Inc. - Common Stock?
The current price of Synlogic, Inc. - Common Stock is 0.9973
When was Synlogic, Inc. - Common Stock last traded?
The last trade of Synlogic, Inc. - Common Stock was at 2:52 pm EDT on April 4th, 2025
What is the market capitalization of Synlogic, Inc. - Common Stock?
The market capitalization of Synlogic, Inc. - Common Stock is 68.03M
How many shares of Synlogic, Inc. - Common Stock are outstanding?
Synlogic, Inc. - Common Stock has 68.21M shares outstanding.